Disclosure Of Effect Of Changes In Foreign Exchange Rates [Text Block]

Hyloris Pharmaceuticals SA - Filing #3166143

Concept 2023-01-01 to
2023-12-31
As at
2023-12-31
2023-01-01 to
2023-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
As at
2022-12-31
2022-01-01 to
2022-12-31
Disclosure of effect of changes in foreign exchange rates [text block]
4
Disclosure of information when currency is not exchangeable into another currency [text block]
Disclosure of information when foreign operation’s functional currency is not exchangeable into presentation currency [text block]
Disclosure of summarised financial information about foreign operation [text block]
Disclosure of summarised financial information about foreign operation [abstract]
Disclosure of summarised financial information about foreign operation [line items]
Non-current assets
12,373,000 EUR
10,927,000 EUR
Current assets
35,308,000 EUR
49,801,000 EUR
Non-current liabilities
1,853,000 EUR
1,047,000 EUR
Current liabilities
6,759,000 EUR
5,772,000 EUR
Revenue
2,087,000 EUR
900,000 EUR
Profit (loss)
15,380,000 EUR
11,906,000 EUR
Other comprehensive income
- EUR
- EUR
Comprehensive income
15,380,000 EUR
15,380,000 EUR
10,770,000 EUR
10,770,000 EUR
11,906,000 EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.